OCULAR THERAPEUTIX, INC Proceeds from Notes Payable
OCULAR THERAPEUTIX, INC (OCUL) reported Proceeds from Notes Payable of $82.47 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC proceeds from notes payable for the quarter ending 2023-12-31 was $0.00.
- OCULAR THERAPEUTIX, INC proceeds from notes payable for the quarter ending 2021-12-31 was $0.00.
- OCULAR THERAPEUTIX, INC proceeds from notes payable for the quarter ending 2021-09-30 was $0.00.
- OCULAR THERAPEUTIX, INC proceeds from notes payable for the quarter ending 2017-12-31 was $0.00.
- OCULAR THERAPEUTIX, INC proceeds from notes payable for fiscal 2023 was $82.47M.
- OCULAR THERAPEUTIX, INC proceeds from notes payable for fiscal 2021 was $3.72M.
- OCULAR THERAPEUTIX, INC proceeds from notes payable for fiscal 2018 was $12.03M, a 225.19% increase from fiscal 2017.
- OCULAR THERAPEUTIX, INC proceeds from notes payable for fiscal 2017 was $3.70M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $82.47M 10-K · filed 2026-02-05 | ||
| 2023-09-30 | $82.47M 10-Q · filed 2024-11-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-11 | $3.72M 10-K · filed 2024-03-11 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $3.72M 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $3.72M 10-Q · filed 2022-08-08 | |||
| 2018-12-31 | $12.03M 10-K · filed 2020-03-12 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $3.70M 10-K · filed 2020-03-12 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $3.70M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $3.70M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $3.70M 10-Q · filed 2018-05-08 | |||
| 2015-12-31 | $1.90M 10-K · filed 2018-03-08 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $0.00 derived: sum of 2 quarters · filed 2017-03-10 | $14.88M 10-K · filed 2017-03-10 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $14.88M 10-Q · filed 2015-11-10 | ||
| 2014-06-30 | $14.88M 10-Q · filed 2015-08-10 | |||
| 2012-12-31 | $4.42M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |